|Other names||Artesunate/pyronaridine tetraphosphate|
Artesunate/pyronaridine, sold under the brand name Pyramax, is a fixed-dose combination medication for the treatment of malaria. It can be used for malaria of both the P. falciparum and P. vivax types. It combines artesunate and pyronaridine. It is taken by mouth.
The combination is generally well tolerated. Side effects may include headache, vomiting, or cough. Use in those with severe liver disease or kidney disease is not recommended. Use is not generally recommended in early pregnancy. However, there are no other options and if treatment may save the mother's life it may be used. The two components work by different mechanisms.
A 2019 review (updated in 2021) found that the combination compared well to artemether/lumefantrine. Benefits also appear similar to mefloquine together with artesunate. It is not recommended for the prevention of malaria.
Research for drug repurposing
- "Application for inclusion in the WHO Model List of essential medicines" (PDF). WHO. Nov 2010. Retrieved 29 June 2017.
- "Pyramax 180 mg/60 mg Film-coated tablet" (PDF). EMA. Retrieved 13 December 2017.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- Pryce, Joseph; Taylor, Melissa; Fox, Tilly; Hine, Paul (2022-06-21). "Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria". The Cochrane Database of Systematic Reviews. 6: CD006404. doi:10.1002/14651858.CD006404.pub4. ISSN 1469-493X. PMC 9209011. PMID 35726133.
- Krishna S, Augustin Y, Wang J, Xu C, Staines HM, Platteeuw H, Kamarulzaman A, Sall A, Kremsner P (January 2021). "Repurposing Antimalarials to Tackle the COVID-19 Pandemic". Trends Parasitol. 37 (1): 8–11. doi:10.1016/j.pt.2020.10.003. PMC 7572038. PMID 33153922.